Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies.

MLA

Chapman, W.Daniel, et al. “Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies.” Current Neurology & Neuroscience Reports, vol. 23, no. 9, Sept. 2023, pp. 521–29. EBSCOhost, https://doi.org/10.1007/s11910-023-01289-9.

APA

Chapman, W. D., Herink, M. C., Cameron, M. H., & Bourdette, D. (2023). Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies. Current Neurology & Neuroscience Reports, 23(9), 521–529. https://doi.org/10.1007/s11910-023-01289-9

Chicago

Chapman, W. Daniel, Megan C. Herink, Michelle H. Cameron, and Dennis Bourdette. 2023. “Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies.” Current Neurology & Neuroscience Reports 23 (9): 521–29. doi:10.1007/s11910-023-01289-9.